9th October 2023
AACR OVARIAN CANCER CONFERENCE PRESENTATION
• Data from preclinical studies in ovarian cancer presented at premier international conference in
Boston, USA.
• Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer
• Data from these studies support clinical study of narmafotinib in ovarian cancer – with plans now commencing with leading international cancer specialists
I’m guessing it is something to do with this conference ...
.
9th October 2023 AACR OVARIAN CANCER CONFERENCE PRESENTATION •...
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.02M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 150000 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 180369 | 2 |
View Market Depth
| Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
| ATX (ASX) Chart |
Day chart unavailable